Kornimate/medical-research-clean huggingface dataset:
postprandial insulin secretion, oxidative stress and gastrointestinal peptides in patients with type 2 diabetes versus healthy subjects

Conditions: Type 2 Diabetes; Postprandial Oxidative Stress

Summary: insulin secretion, plasma lipids, oxidative stress markers and gastrointestinal peptides will be measured in patients with type 2 diabetes versus healthy subjects in a fasting status and in response to standard meals (at times 0', 30', 60', 120' and 180').


Eligibility criteria:
inclusion criteria: * 40 individuals with type 2 diabetes treated by diet only or oral hypogylycemic agents, * diabetes duration at least 1 year, * both men and women, * age 30-65 years, * bmi 27-50 kg/m². the subjects will be explained aims, methods and risks of the study and they will sign informed consent exclusion criteria: * gravidity, * lactation, * drug abuse, * insulin therapy

Keywords: diet gastrointestinal peptides insulin secretion oxidative stress plasma lipids postprandial type 2 diabetes
characteristics and risk factors for invasive fungal infection with acute-on-chronic hepatitis b liver failure

Conditions: Acute-on-chronic Hepatitis B Liver Failure

Summary: this is a single-center retrospective study. the clinical data of patients with acute-on-chronic hepatitis b liver failure who were hospitalized in the department of hepatology, qilu hospital of shandong university from january 2010 to july 2023 were collected.

the clinical data of patients with acute-on-chronic hepatitis b liver failure who were hospitalized in the department of hepatology, qilu hospital of shandong university from january 2010 to july 2023 were collected, including age, gender, hbsag,hbeag, serum hepatitis b virus dna, alanine aminotransferase, aspartate aminotransferase, platelet, white blood cell,neutrophilic granulocyte percentage, neutrophile granulocyte, total bilirubin, creatinine, international normalized ratio,procalcitonin,globulin. prothrombin time activity, 1, 3 - beta glucan d test, galactomannan test, sputum culture, imaging ct and other indicators. our study followed up patients with acute-on-chronic hepatitis b liver failure with fungal infection during hospitalization to clarify the clinical characteristics and risk factors of fungal infection in the development of acute-on-chronic hepatitis b liver failure , and to provide clinical prevention and treatment recommendations for fungal infection in patients with acute-on-chronic hepatitis b liver failure . thus, the prognosis of patients can be improved and the survival rate can be increased.

Eligibility criteria:
inclusion criteria: * acute liver function injury tbil≥5mg/dl(85umol/l) and international normalized ratio (inr) ≥1.5 or pta≤40% based on previously known chronic hepatitis b or compensated cirrhosis. * combined with ascites and/or hepatic encephalopathy within 4 weeks. * hbsag（+)\>6 months exclusion criteria: * patients died within 48 hours of admission or withdrew treatment. * combined with liver cancer and other extrahepatic organ malignant tumors, rheumatic diseases, hyperthyroidism. * age \<18 years old.
a study of aidsvax b/b and aidsvax b/e, two possible vaccines

Conditions: HIV Infections

Summary: the purpose of this study is to see if it is safe and effective to give aidsvax b/b or aidsvax b/e, two potential hiv vaccines, to hiv-negative volunteers.

patients are randomized to 1 of the 2 following arms and administered 1 or 2 injections into the deltoid muscle at 0, 1, 6, and 12 months: arm a: patients receive 1 of 3 doses of aidsvax b/b vaccine (mn rgp120/hiv-1 plus gne8 rgp120/hiv-1) in alum adjuvant. arm b: patients receive aidsvax b/e (mn rgp120/hiv-1 plus a244 rgp120/hiv-1) vaccine in alum adjuvant. patients are evaluated at 1 hr, 3 days, and 14 days after each immunization and at 18 months after the first immunization. an interim analysis is performed after all patients receive the second dose (at 1 month).

Eligibility criteria:
patients must: be hiv-uninfected men and women at low or intermediate risk for hiv-1 infection.

Keywords: hiv-1 dose-response relationship, drug acquired immunodeficiency syndrome aids vaccines hiv seronegativity antigens, viral alum compounds
a study of azacitidine in participants with international prognostic scoring system (ipss) intermediate-2 and high-risk myelodysplastic syndromes (mds), or chronic myelomonocytic leukemia (cmml), or acute myeloid leukemia (aml)

Conditions: Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute

Summary: the purpose of this study is to assess the safety and effectiveness in the real-world setting among participants who are treated with azacitidine in accordance with the china product label.

this study will have participants both enrolled retrospectively and prospectively for azacitidine (aza) treatment.

Eligibility criteria:
inclusion criteria: * documented diagnosis of intermediate-2/ high-risk myelodysplastic syndromes (mds) or chronic myelomonocytic leukemia (cmml) or acute myeloid leukemia (aml) with 20-30% bone marrow blasts and multi-lineage dysplasia * initiated azacitidine (aza) treatment per approved china product label after april 2017 exclusion criteria: * contraindicated for the use of aza according to china product label * simultaneously participating in a treatment intervention study other protocol-defined inclusion/exclusion criteria apply.

Keywords: myelodysplastic syndromes (mds) azacitidine (aza) chronic myelomonocytic leukemia (cmml) acute myeloid leukemia (aml)
embrace: seizure characterization

Conditions: Epilepsy

Summary: the study is intended to characterize sleep, stress, and seizures in daily life with the empatica embrace watch and smartphone-based diary-alert system. the primary study objective is to collect and validate biometric signals from epilepsy patients using the empatica embrace watch and compare them to ictal events captured from human (patient and caregiver) reports.

patients use the embrace sensor with a smartphone app, "alert". the sensor attempts to capture convulsive seizure events such as generalized tonic-clonic seizures (gtcs's), and to initiate an alert when such an event is captured. patients can also enter seizures (captured or not, gtcs or not) into the "mate" diary, and they can cancel or mark false alarms if embrace triggered a false alarm.

Eligibility criteria:
inclusion criteria: * participants must be between the ages of 1-99 * anyone (healthy or not) can participate * adult participant must either be able to give consent or must have an acceptable surrogate capable of giving consent on their behalf. * participants under age 18 must have an adult guardian give informed consent, and if capable, the patient must give informed assent. * participants with gtcs must have a functioning smartphone (ios or android) that can be paired with the embrace over a bluetooth low energy connection and agree that it can be kept on or near their person. * participants with gtcs (or their surrogate) must be able to identify one or more "designated frequent caregivers," who has a functioning phone, agrees to keep it regularly charged, agrees to receive alerts, and agrees to respond to alerts promptly to the best of their ability. * participants must be fluent in the language of the consent forms (currently limited to english but spanish and other languages are planned). * participants must reside in the united states. exclusion criteria: * participants must not have broken or injured skin at the wrist or leg location where embrace is worn, and they must be able to tolerate wearing embrace snugly for long periods of time. thus, they should not have allergies to the material composition of the embrace watch, or discomfort wearing a wristwatch or leg-band device. * participants should not be homeless. * participants should not have active dependence on substances that are not currently prescribed by their doctor (e.g. alcohol, pain medications, illegal drugs) or be taking substances that they are not willing to disclose as a study participant. * participants must not be pregnant or planning to become pregnant within six months at the time of screening.
vaginal progesterone as maintenance treatment after an episode of preterm labor (promise study)

Conditions: Threatened Premature Labor

Summary: eligible patients will be informed and asked to enroll in the study at hospital admission. a transvaginal ultrasound examination will be performed to determine cervical length. if an eligible woman accepts to participate, patient will be randomized to one of the study arms assigned in a double blind basis. patient will receive the medication (vaginal capsule of progesterone or placebo). the patient will administer herself one vaginal capsule in a daily basis since gestational age of 36 weeks and 6 days as the primary endpoint is to demonstrate that the use of a maintenance treatment with vaginal progesterone is able to reduce the incidence of preterm birth before 34.0 and 37.0 gestational weeks. after delivery, perinatal and neonatal data will be collected.


Eligibility criteria:
inclusion criteria: * pregnant women aged between 18 - 45 years * gestational age between 24.0 and before 33.6 gestational weeks * singleton pregnancy * patients admitted because of preterm labor who have been successfully treated of any tocolytic drugs (β-mimetics drugs, nifedipine, atosiban) * ultrasound cervical length at discharge \< 25 mm * signed patient consent form (ci) exclusion criteria: * known or suspected infection, premature rupture of membranes or any other pathological gravid maternal or fetal condition coexisting at hospital admission (pre-eclampsia, rciu) which may induce iatrogenic labor. * present or previous liver disease, present or previous cholestasis gravidarum, abnormal hepatic blood tests. * with known allergy to progesterone or peanuts (excipient). * grade 2 (or upper) renal or liver laboratory abnormalities * treated from dependent-hormone malignant cancer (i.e., breast carcinoma...) * with diabetes mellitus or insulinized gestational diabetes * treated with heparin * drug abuse * inadequate treatment compliance
feasibility and acceptability of an online program to promote physical activity among black women

Conditions: Sedentary Behavior; Lack of Physical Activity; Physical Inactivity

Summary: this study will identify strategies for modifying a physical activity intervention, previously delivered in a face-to-face format, for online implementation.

research demonstrates the health-related benefits of participation in daily physical activity (pa), including prevention and treatment of chronic diseases. despite this knowledge, the majority of us adults, particularly black women, do not achieve recommended levels of pa and, consequently, have higher rates of related chronic disease. an efficacy study led by the proposed principal investigator developed and tested an in person, 10-month group-based faith-integrated (fi) or secular (sec) pa intervention, compared with a self-guided control (sg) for black women. both fi and sec were superior to sg for increasing daily steps after 10 months, and fi was superior to sg for increasing daily steps 12 months post intervention. barriers to program participation noted by participants included childcare and work responsibilities and proximity to the group meeting location. the 2018 pa guidelines advisory committee scientific report highlighted the need for effective strategies to promote pa, including internet-delivered interventions which have demonstrated strong evidence for effectiveness at increasing pa levels. limited data exist regarding the efficacy of internet-delivered interventions in racial/ethnic minority groups. online delivery of our evidence-based program may increase reach and address known barriers to pa program participation in black women. this project will explore strategies for adapting the program for web-based delivery of the existing curriculum. r21 phase aims are: aim 1: solicit input from individuals representative of the population of focus to inform the translation of the fi curriculum for online use; aim 2: use the knowledge gathered in aim 1 to adapt existing fi and sg curricula for online use; aim 3: assess acceptability of the online curricula in an advisory group similar to the target population. investigators will conduct focus groups with black women to understand factors that would influence online delivery of the curriculum. a 12-member advisory group will be convened to assist with developing materials/strategies to adapt the curriculum for online delivery. in an iterative approach where material is tested, refined, and retested until complete, investigators will engage the advisory group in feasibility testing of the online curriculum

Eligibility criteria:
1. self-identified female 2. black/african american 3. \> 18 years of age 4. self-reported low active (i.e., achieving \< 150 minutes per week of moderate-to-vigorous physical activity) 5. no physical limitations or medical conditions that would be impacted by physical activity 6. own a smartphone or computer with reliable high speed internet access 7. able to speak and read english fluently; 8) potentially interested in participating in an online health intervention.
discontinuation order of vasopressors in septic shock

Conditions: Septic Shock

Summary: the purpose of this study is to evaluate the incidence of hypotension based on the discontinuation order of norepinephrine and vasopressin in patients receiving concomitant norepinephrine and vasopressin infusions for the treatment of septic shock.

there are little data regarding the discontinuation of vasopressors in patients with septic shock. therefore, the investigators intend to evaluate the incidence of hypotension based on the discontinuation order of norepinephrine and vasopressin in patients receiving concomitant norepinephrine and vasopressin infusions for the treatment of septic shock.

Eligibility criteria:
inclusion criteria: * patients 20 years of age or older * patients of receiving concomitant therapy with norepinephrine and vasopressin for teh management of septic shock * patients began to reduce the vasopressor exclusion criteria: * patients who expired or had care withdrawn while receiving norepinephrine and vasopressin * patients being transferred into the icu from an outside facility or the operating room * patients who are suspected to have vasopressin deficiency (eg. hpa axis dysfunction, empty sella) * acute myocardial infarction or congestive heart failure (nyha functional classification iii or iv) * acute mesenteric ischemia * patients who were received other vasopressor except for norepinephrine or vasopressin

Keywords: septic shock norepinephrine vasopressin hypotension
bifurcation coronary lesion 0-0-1

Conditions: Coronary Bifurcation Stenosis

Summary: research involving human persons (rihp 3) focusing on the treatment of type 0-0-1 bifurcation lesions in routine practice. multicenter study. to retrieve and analyze the details of different angioplasty techniques used in this type of bifurcation lesion (medina 0-0-1) in order to describe current practice and search for predictors of clinical events.

the primary objective of the trial is to estimate the frequency of major adverse cardiac events (mace), including cardiac death, myocardial infarction within the territory of the treated lesion, and revascularization of the target lesion in a representative population of patients treated by coronary angioplasty of type 0-0-1 bifurcation lesions. the sample size will be determined by the number of angioplasties of type 0-0-1 bifurcation lesions performed at each center between 2016 and 2022. since the trial is observational in nature and there are no previously published studies, the sample size cannot be calculated based on the desired precision of the estimation. furthermore, the purpose of the study is also to assess the techniques used to treat this type of coronary bifurcation and to highlight any differences between different centers and with other types of coronary bifurcation lesions described in the literature.

Eligibility criteria:
inclusion criteria: * male or female aged 18 years and older, * who underwent angioplasty for a coronary bifurcation lesion of type 0-0-1 between 2016 and 2022. exclusion criteria: - opposing the collection and processing of necessary data and refusing additional telephone follow-up
tirellizumab combined with chemotherapy monotherapy for non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer

Summary: this is a prospective, single-arm, single-center, exploratory clinical trial to evaluate the efficacy and safety of the pd-1 antibody tirelizumab combined with chemotherapy monotherapy in patients with relapsed/metastatic non-small cell lung cancer.

this is a prospective, single-arm, single-center, exploratory clinical trial to evaluate the efficacy and safety of the pd-1 antibody tirellizumab combined with chemotherapy monotherapy in patients with relapsed/metastatic non-small cell lung cancer. this study prospectively collected disease history, treatment history, demographic data, baseline data during treatment, each treatment visit data, efficacy data, and safety data of nsclc patients with egfr and alk driver negative ecog ps 2 scores treated with tirellizumab combined with monotherapy. the subjects did not voluntarily withdraw from the test or the researchers believed that the subjects were not suitable for further test. each subject will be treated until the disease progresses or the toxic and side effects caused by the drugs are intolerable, and the follow-up treatment plan, treatment status and survival data of the patients still need to be collected.

Eligibility criteria:
inclusion criteria: 1. pathologically confirmed recurrent/metastatic non-small cell lung cancer with local recurrence or distant metastasis after prior radiotherapy and/or surgery, or with distant metastasis at the time of admission. 2. the age range is between 18 and 85. 3. predicted survival ≥12 weeks. exclusion criteria: 1. patients with other malignant tumors. 2. positive tests for egfr mutation and alk fusion gene have been confirmed. 3. partial comorbidity. 4. other.
a phase 1 study to evaluate aln-4324 in overweight to obese healthy volunteers

Conditions: Obese or Overweight Healthy Volunteers

Summary: the purpose of this study is to evaluate the safety and tolerability of single ascending doses of aln-4324 in healthy volunteers and to characterize the single-dose pk of aln-4324.


Eligibility criteria:
inclusion criteria: * has a body mass index (bmi) of ≥27 kg/m\^2 and \<40 kg/m\^2 exclusion criteria: * has known human immunodeficiency virus (hiv) infection; or known current or chronic hepatitis c virus or hepatitis b virus infection note: other protocol defined inclusion/exclusion criteria apply

Keywords: sirna rnai therepeutic
genetic study of familial and sporadic als/motor neuron disease, miyoshi myopathy and other neuromuscular disorders

Conditions: Amyotrophic Lateral Sclerosis; Frontotemporal Dementia; PLS; Motor Neuron Disease; Lou Gehrigs Disease; Familial Disease; Amyotrophic Lateral Sclerosis, Sporadic; Muscular Dystrophy; Miyoshi Myopathy; Amyotrophic Lateral Sclerosis With Dementia

Summary: the investigators laboratory has been studying families with a history of als for more than 30 years and is continuing to use new ways to understand how genes may play a role in als, motor neuron disease and other neuromuscular disorders. the purpose of this study is to identify additional genes that may cause or put a person at risk for either familial als (meaning 2 or more people in a family who have had als), sporadic als, or other forms of motor neuron disease in the hopes of improving diagnosis and treatment. as new genes are found that may be linked to als in families or individuals, the investigators can then further study how that gene may be contributing to the disease by studying it down to the protein and molecular level. this includes all forms of als, motor neuron disease and als with fronto-temporal dementia(als/ftd). we also continue to study other forms of neuromuscular disease such as miyoshi myopathy, fsh dystrophy and other forms of muscular dystrophy by looking at the genes that may be associated with them. there have been a number of genes identified that are associated with both familial and sporadic als, with the sod1, c9orf72, and fus genes explaining the majority of the cases. however, for about 25% of families with fals, the gene(s) are still unknown. the investigators also will continue to work with families already identified to carry one of the known genes associated with als.

participants will be asked to provide a blood sample ( or sometimes saliva or skin sample) and to complete a couple of questionnaires regarding their overall medical health. medical records will need to be reviewed for all those diagnosed with one of the study diseases to allow the researchers to review details of their clinical disease symptoms, neurological exams and test results. participants do not need to travel to massachusetts for this study. samples can be obtained locally at no costs to the participant. family members may be included in the study depending on family history and their relationship to the affected individual.

Eligibility criteria:
inclusion criteria: * diagnosis of or family history of als,mnd,als with dementia, or pls. * diagnosis of miyoshi myopathy * willingness to provide a blood sample for study use exclusion criteria: * unwilling to provide a blood or saliva sample

Keywords: fals als sals mnd sod1 als genes pls pma als/ftd familial als sporadic als genetics ftd miyoshi myopathy